Integra Lifesciences Holdings (IART) Accumulated Expenses (2009 - 2026)

Integra Lifesciences Holdings has disclosed Accumulated Expenses across 18 years of filings, most recently posting $107.6 million for Q2 2026.

• In Q2 2026, Accumulated Expenses fell 18.09% year-over-year to $107.6 million; the TTM figure through Jun 2026 stood at $107.6 million (down 18.09% YoY), while the FY2025 annual figure was $130.5 million, up 7.04% from the prior year.
• Accumulated Expenses came in at $107.6 million for Q2 2026 at Integra Lifesciences Holdings, down from $133.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $137.4 million in Q1 2025 to a low of $79.0 million in Q3 2022.
• Average Accumulated Expenses over 5 years is $109.5 million, with a median of $106.5 million recorded in 2022.
• Year-over-year, Accumulated Expenses sank 33.56% in 2022 and jumped 46.1% in 2024.
• Over 5 years, Accumulated Expenses stood at $80.0 million in 2022, then rose by 26.0% to $100.8 million in 2023, then gained by 20.89% to $121.9 million in 2024, then advanced by 7.04% to $130.5 million in 2025, then fell by 17.53% to $107.6 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $107.6 million in Q2 2026, $133.3 million in Q1 2026, and $130.5 million in Q4 2025.